NDAN/ASOLUTIONPriority Review
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
DEFENCATH (taurolidine and heparin) by CorMedix. Approved for anti-coagulant [epc]. First approved in 2023.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEFENCATH is a taurolidine and heparin solution indicated as an anti-coagulant for extracorporeal circuits (EPC), approved in November 2023. The combination leverages taurolidine's antimicrobial properties with heparin's anticoagulation to prevent thrombosis in dialysis and other blood circuit applications. This small molecule solution targets patients requiring vascular access protection during medical procedures.
Growth15.8 years to LOE
As a recently approved product in growth phase with no established competitive pressure, early-stage brand teams will focus on market penetration and establishing clinical adoption in dialysis centers and hospital systems.
Mechanism of Action
Pharmacologic Class:
Anti-coagulant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Started May 2025
200 enrolled
Central Line Associated Blood Stream Infections (CLABSI)
Expanded Access Program for Patients at Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
Catheter-related Bloodstream Infection
Career Relevance
DEFENCATH represents an early-stage commercial opportunity at CorMedix with potential for team expansion as the product scales within nephrology and interventional settings. Career growth will depend on successful market penetration in dialysis centers and establishment of clinical adoption benchmarks.
Worked on DEFENCATH at CorMedix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.